Effective imaging device development programs involve a highly organized group of individuals who create and adhere to a strict protocol, developed by consensus, before reporting to the US FDA.
Today, more than ever before, biopharma companies are coming under pressure to demonstrate the value of their products in meaningful terms to varied stakeholders and audiences. By Quintiles
Quintiles' John Hall tells NGP of the burning issues in the biopharmaceutical industry.
Christene Leiper of Onorach explains how identifying key challenges and improving site management can save time and reduce costs.
Celgene Corporation’s Kamal Shah looks at why most new drug compounds fail to progress beyond the clinical trial stage.